Modified nonsink equation for permeability estimation in cell monolayers: Comparison with standard methods

Molecular Pharmaceutics

Volumn 11, Issue 5, 2014, Pages 1403-1414

  Mangas Sanjuan, Victor ^a,b   González Álvarez, Isabel ^a   González Álvarez, Marta ^a   Casabó, Vicente G ^b   Bermejo, Marival ^a  

^a MIGUEL HERNÁNDEZ UNIVERSITY   (Spain)

^b UNIVERSITY OF VALENCIA   (Spain)

Author keywords

BCS classification; cell monolayer; in vitro method; model simulation; permeability; permeability estimation method; variability

Indexed keywords

ATENOLOL; METOPROLOL; NORFLOXACIN; VERAPAMIL; ZIDOVUDINE;

ARTICLE; BIOEQUIVALENCE; CALCULATION; CELL CULTURE; CELL MEMBRANE PERMEABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG DEVELOPMENT; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IN VITRO STUDY; IN VIVO STUDY; LINEAR REGRESSION ANALYSIS; MATHEMATICAL ANALYSIS; MATHEMATICAL MODEL; MODIFIED NONSINK EQUATION; PERMEABILITY; PREDICTION; PRIORITY JOURNAL; REGRESSION ANALYSIS; THEORETICAL MODEL;

MODELS, THEORETICAL; PERMEABILITY; REGRESSION ANALYSIS;

EID: 84899802996     PISSN: 15438384     EISSN: 15438392     Source Type: Journal    
DOI: 10.1021/mp400555e     Document Type: Article

References (55)

1. Buckley, S. T.; Fischer, S. M.; Fricker, G.; Brandl, M. In vitro models to evaluate the permeability of poorly soluble drug entities: challenges and perspectives Eur. J. Pharm. Sci. 2012, 45 (3) 235-50
2. Amidon, G. L.; Lennernas, H.; Shah, V. P.; Crison, J. R. A theoretical basis for a biopharmaceutic drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability Pharm. Res. 1995, 12 (3) 413-20
3. FDA. Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate-Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System; Center for Drug Evaluation and Research: August 2000.
4. EMA. GUIDELINE ON THE INVESTIGATION OF BIOEQUIVALENCE; European Medicines Agency: 1 August 2010.
5. WHO. WHO EXPERT COMMITTEE ON SPECIFICATIONS FOR PHARMACEUTICAL PREPARATIONS. 2006.
6. Di, L.; Kerns, E. H.; Carter, G. T. Strategies to assess blood-brain barrier penetration Expert Opin. Drug Discovery 2008, 3 (6) 677-87
7. Kessler, R. C.; Demler, O.; Frank, R. G.; Olfson, M.; Pincus, H. A.; Walters, E. E.; Wang, P.; Wells, K. B.; Zaslavsky, A. M. Prevalence and treatment of mental disorders, 1990 to 2003 N. Engl. J. Med. 2005, 352 (24) 2515-23
8. Kola, I.; Landis, J. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discovery 2004, 3 (8) 711-5
9. Pangalos, M. N.; Schechter, L. E.; Hurko, O. Drug development for CNS disorders: strategies for balancing risk and reducing attrition Nat. Rev. Drug Discovery 2007, 6 (7) 521-32
10. Bickel, U. How to measure drug transport across the blood-brain barrier NeuroRx 2005, 2 (1) 15-26
11. Broccatelli, F.; Larregieu, C. A.; Cruciani, G.; Oprea, T. I.; Benet, L. Z. Improving the prediction of the brain disposition for orally administered drugs using BDDCS Adv. Drug Delivery Rev. 2012, 64 (1) 95-109
12. Cabrera, M. A.; Bermejo, M.; Perez, M.; Ramos, R. TOPS-MODE approach for the prediction of blood-brain barrier permeation J. Pharm. Sci. 2004, 93 (7) 1701-17
13. Carrara, S.; Reali, V.; Misiano, P.; Dondio, G.; Bigogno, C. Evaluation of in vitro brain penetration: optimized PAMPA and MDCKII-MDR1 assay comparison Int. J. Pharm. 2007, 345 (1-2) 125-33
14. Culot, M.; Lundquist, S.; Vanuxeem, D.; Nion, S.; Landry, C.; Delplace, Y.; Dehouck, M. P.; Berezowski, V.; Fenart, L.; Cecchelli, R. An in vitro blood-brain barrier model for high throughput (HTS) toxicological screening Toxicol. In Vitro 2008, 22 (3) 799-811
15. Friden, M.; Ducrozet, F.; Middleton, B.; Antonsson, M.; Bredberg, U.; Hammarlund-Udenaes, M. Development of a high-throughput brain slice method for studying drug distribution in the central nervous system Drug Metab. Dispos. 2009, 37 (6) 1226-33
16. Friden, M.; Gupta, A.; Antonsson, M.; Bredberg, U.; Hammarlund-Udenaes, M. In vitro methods for estimating unbound drug concentrations in the brain interstitial and intracellular fluids Drug Metab. Dispos. 2007, 35 (9) 1711-9
17. Friden, M.; Winiwarter, S.; Jerndal, G.; Bengtsson, O.; Wan, H.; Bredberg, U.; Hammarlund-Udenaes, M.; Antonsson, M. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids J. Med. Chem. 2009, 52 (20) 6233-43
18. Geldenhuys, W. J.; Manda, V. K.; Mittapalli, R. K.; Van der Schyf, C. J.; Crooks, P. A.; Dwoskin, L. P.; Allen, D. D.; Lockman, P. R. Predictive screening model for potential vector-mediated transport of cationic substrates at the blood-brain barrier choline transporter Bioorg. Med. Chem. Lett. 2010, 20 (3) 870-7
19. Hammarlund-Udenaes, M.; Bredberg, U.; Friden, M. Methodologies to assess brain drug delivery in lead optimization Curr. Top. Med. Chem. 2009, 9 (2) 148-62
20. Hansen, D. K.; Scott, D. O.; Otis, K. W.; Lunte, S. M. Comparison of in vitro BBMEC permeability and in vivo CNS uptake by microdialysis sampling J. Pharm. Biomed. Anal. 2002, 27 (6) 945-58
21. Hanson, L. R.; Frey, W. H., 2nd Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease BMC Neurosci. 2008, 9 (Suppl. 3) S5
22. Kataoka, M.; Masaoka, Y.; Yamazaki, Y.; Sakane, T.; Sezaki, H.; Yamashita, S. In vitro system to evaluate oral absorption of poorly water-soluble drugs: simultaneous analysis on dissolution and permeation of drugs Pharm. Res. 2003, 20 (10) 1674-80
23. Lacombe, O.; Videau, O.; Chevillon, D.; Guyot, A. C.; Contreras, C.; Blondel, S.; Nicolas, L.; Ghettas, A.; Benech, H.; Thevenot, E.; Pruvost, A.; Bolze, S.; Krzaczkowski, L.; Prevost, C.; Mabondzo, A. In vitro primary human and animal cell-based blood-brain barrier models as a screening tool in drug discovery Mol. Pharmaceutics 2011, 8 (3) 651-63
24. Mabondzo, A.; Bottlaender, M.; Guyot, A. C.; Tsaouin, K.; Deverre, J. R.; Balimane, P. V. Validation of in vitro cell-based human blood-brain barrier model using clinical positron emission tomography radioligands to predict in vivo human brain penetration Mol. Pharmaceutics 2010, 7 (5) 1805-15
25. Wan, H.; Rehngren, M.; Giordanetto, F.; Bergstrom, F.; Tunek, A. High-throughput screening of drug-brain tissue binding and in silico prediction for assessment of central nervous system drug delivery J. Med. Chem. 2007, 50 (19) 4606-15
26. Wang, Q.; Rager, J. D.; Weinstein, K.; Kardos, P. S.; Dobson, G. L.; Li, J.; Hidalgo, I. J. Evaluation of the MDR-MDCK cell line as a permeability screen for the blood-brain barrier Int. J. Pharm. 2005, 288 (2) 349-59
27. Mangas-Sanjuan, V.; Gonzalez-Alvarez, I.; Gonzalez-Alvarez, M.; Casabo, V. G.; Bermejo, M. Innovative in vitro method to predict rate and extent of drug delivery to the brain across the Blood-Brain Barrier Mol. Pharmaceutics 2013, 10 (10) 3822-31
28. Tavelin, S.; Grasjo, J.; Taipalensuu, J.; Ocklind, G.; Artursson, P. Applications of epithelial cell culture in studies of drug transport Methods Mol. Biol. 2002, 188, 233-72
29. Palm, K.; Luthman, K.; Ros, J.; Grasjo, J.; Artursson, P. Effect of molecular charge on intestinal epithelial drug transport: pH-dependent transport of cationic drugs J. Pharmacol. Exp. Ther. 1999, 291 (2) 435-43
30. Jonsson, S.; Henningsson, A.; Edholm, M.; Salmonson, T. Role of modelling and simulation: a European regulatory perspective Clin. Pharmacokinet. 2012, 51 (2) 69-76
31. Sheiner, L. B. Learning versus confirming in clinical drug development Clin. Pharmacol. Ther. 1997, 61 (3) 275-91
32. Breimer, D. D.; Danhof, M. Relevance of the application of pharmacokinetic-pharmacodynamic modelling concepts in drug development. The "wooden shoe" paradigm Clin. Pharmacokinet. 1997, 32 (4) 259-67
33. Derendorf, H.; Meibohm, B. Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives Pharm. Res. 1999, 16 (2) 176-85
34. Holford, N. H.; Kimko, H. C.; Monteleone, J. P.; Peck, C. C. Simulation of clinical trials Annu. Rev. Pharmacol. Toxicol. 2000, 40, 209-34
35. Aarons, L.; Karlsson, M. O.; Mentre, F.; Rombout, F.; Steimer, J. L.; van Peer, A. Role of modelling and simulation in Phase I drug development Eur. J. Pharm. Sci. 2001, 13 (2) 115-22
36. Chaikin, P.; Rhodes, G. R.; Bruno, R.; Rohatagi, S.; Natarajan, C. Pharmacokinetics/pharmacodynamics in drug development: an industrial perspective J. Clin. Pharmacol. 2000, 40 (12 Part 2) 1428-38
37. Reigner, B. G.; Williams, P. E.; Patel, I. H.; Steimer, J. L.; Peck, C.; van Brummelen, P. An evaluation of the integration of pharmacokinetic and pharmacodynamic principles in clinical drug development. Experience within Hoffmann La Roche Clin. Pharmacokinet. 1997, 33 (2) 142-52
38. Lockwood, P.; Ewy, W.; Hermann, D.; Holford, N. Application of clinical trial simulation to compare proof-of-concept study designs for drugs with a slow onset of effect; an example in Alzheimer's disease Pharm. Res. 2006, 23 (9) 2050-9
39. FDA Innovation or stagnation: challenge and opportunity on the critical path to new medical products. http://www.fda.gov/ScienceResearch/SpecialTopics/ CriticalPathInitiative/CriticalPathOpportunitiesReports/ucm077262.htm (Accessed 2 May 2010).
40. Edholm, M.; Gil Berglund, E.; Salmonson, T. Regulatory aspects of pharmacokinetic profiling in special populations: a European perspective Clin. Pharmacokinet. 2008, 47 (11) 693-701
41. Manolis, E.; Pons, G. Proposals for model-based paediatric medicinal development within the current European Union regulatory framework Br. J. Clin. Pharmacol. 2009, 68 (4) 493-501
42. Bevington, P. R.; Robinson, D. K. Data reduction and error analysis for the physical sciences, 2 nd ed.; McGraw-Hill: New York, 1992.
43. Pham-The, H.; Garrigues, T.; Bermejo, M.; Gonzalez-Alvarez, I.; Monteagudo, M. C.; Cabrera-Perez, M. A. Provisional classification and in silico study of biopharmaceutical system based on caco-2 cell permeability and dose number Mol. Pharmaceutics 2013, 10 (6) 2445-61
44. Pham-The, H.; González-álvarez, I.; Bermejo, M.; Mangas-Sanjuan, V.; Centelles, I.; Garrigues, T. M.; Cabrera-Pérez, M. A. In Silico Prediction of Caco-2 Cell Permeability by a Classification QSAR Approach Mol. Inf. 2011, 30 (4) 376-85
45. Kim, J. S.; Mitchell, S.; Kijek, P.; Tsume, Y.; Hilfinger, J.; Amidon, G. L. The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests Mol. Pharmaceutics 2006, 3 (6) 686-94
46. Sarmento, B.; Andrade, F.; da Silva, S. B.; Rodrigues, F.; das Neves, J.; Ferreira, D. Cell-based in vitro models for predicting drug permeability Expert Opin. Drug Metab. Toxicol. 2012, 8 (5) 607-21
47. Skolnik, S.; Lin, X.; Wang, J.; Chen, X. H.; He, T.; Zhang, B. Towards prediction of in vivo intestinal absorption using a 96-well Caco-2 assay J. Pharm. Sci. 2010, 99 (7) 3246-65
48. Turco, L.; Catone, T.; Caloni, F.; Di Consiglio, E.; Testai, E.; Stammati, A. Caco-2/TC7 cell line characterization for intestinal absorption: how reliable is this in vitro model for the prediction of the oral dose fraction absorbed in human? Toxicol. In Vitro 2011, 25 (1) 13-20
49. Volpe, D. A. Drug-permeability and transporter assays in Caco-2 and MDCK cell lines Future Med. Chem. 2011, 3 (16) 2063-77
50. Youdim, K. A.; Avdeef, A.; Abbott, N. J. In vitro trans-monolayer permeability calculations: often forgotten assumptions Drug Discovery Today 2003, 8 (21) 997-1003
51. Bermejo, M.; Avdeef, A.; Ruiz, A.; Nalda, R.; Ruell, J. A.; Tsinman, O.; Gonzalez, I.; Fernandez, C.; Sanchez, G.; Garrigues, T. M.; Merino, V. PAMPA - a drug absorption in vitro model 7. Comparing rat in situ, Caco-2, and PAMPA permeability of fluoroquinolones Eur. J. Pharm. Sci. 2004, 21 (4) 429-41
52. Hilgendorf, C.; Spahn-Langguth, H.; Regardh, C. G.; Lipka, E.; Amidon, G. L.; Langguth, P. Caco-2 versus Caco-2/HT29-MTX co-cultured cell lines: permeabilities via diffusion, inside- and outside-directed carrier-mediated transport J. Pharm. Sci. 2000, 89 (1) 63-75
53. Volpe, D. A. Variability in Caco-2 and MDCK cell-based intestinal permeability assays J. Pharm. Sci. 2008, 97 (2) 712-25
54. Gonzalez-Alvarez, I.; Fernandez-Teruel, C.; Garrigues, T. M.; Casabo, V. G.; Ruiz-Garcia, A.; Bermejo, M. Kinetic modelling of passive transport and active efflux of a fluoroquinolone across Caco-2 cells using a compartmental approach in NONMEM Xenobiotica 2005, 35 (12) 1067-88
55. Troutman, M. D.; Thakker, D. R. Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium Pharm. Res. 2003, 20 (8) 1210-24